StockData
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc (GALT) stock

GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.91−0.11 (-3.64%)

Close on Nov 17, 2026Market cap $293.47MP/E –Yield –

Galectin Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Galectin Therapeutics's ebitda for the twelve months ending Dec 31, 2017 was -$16.25M. For fiscal 2024 it was -$42.43M. The highest annual figure on record is -$4.87M in fiscal 2010.

Annual ebitda

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$42.43M–
FY2023Dec 31, 2023-$38.07M–
FY2022Dec 31, 2022-$38.35M–
FY2021Dec 31, 2021-$30.18M–
FY2020Dec 31, 2020-$23.44M–
FY2019Dec 31, 2019-$13.44M–
FY2018Dec 31, 2018-$13.60M–
FY2017Dec 31, 2017-$16.25M–
FY2016Dec 31, 2016-$21.47M–
FY2015Dec 31, 2015-$20.07M–
FY2014Dec 31, 2014-$15.42M–
FY2013Dec 31, 2013-$12.09M–
FY2012Dec 31, 2012-$9.89M–
FY2011Dec 31, 2011-$10.40M–
FY2010Dec 31, 2010-$4.87M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2017Dec 31, 2017-$2.37M–
Q3 FY2017Sep 30, 2017-$4.41M–
Q2 FY2017Jun 30, 2017-$4.51M–
Q1 FY2017Mar 31, 2017-$4.95M–
Q4 FY2016Dec 31, 2016-$4.60M–
Q3 FY2016Sep 30, 2016-$4.54M–

More Galectin Therapeutics figures

See a number that looks wrong?